SCHEMBL22845409

SCHEMBL22845409

CCOC(=O)c1cnn2c3c(c(=O)n(-c4ccccc4)c12)CCN(C(=O)c1ccc(Cl)c(Cl)c1)C3

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
P2RX7 Q99572 2/20 0.40
TACR3 P29371 1/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 5/20 0.37
DCTPP1 Q9H773 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
P2RY12 Q9H244 3/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845213 0.89 MTHFD2 (0.43) P2RX7TACR3LMNAALDH1A1MAPT
SCHEMBL22845214 0.86 LMNA (0.37) P2RX7TACR3LMNAALDH1A1POLB
SCHEMBL22845293 0.84 HPGD (0.40) TSHRP2RX7TACR3LMNAALDH1A1
SCHEMBL22845202 0.84 LMNA (0.40) TACR3LMNAALDH1A1POLBMAPT
SCHEMBL22845327 0.84 TACR3 (0.40) P2RX7TACR3LMNAALDH1A1MAPT
SCHEMBL22845286 0.83 LMNA (0.40) P2RX7TACR3LMNAALDH1A1POLB
SCHEMBL22845287 0.81 LMNA (0.37) P2RX7TACR3LMNAALDH1A1POLB
SCHEMBL22845368 0.81 PREP (0.40) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL26842626 0.81 LMNA (0.40) P2RX7TACR3LMNAALDH1A1POLB
SCHEMBL24173921 0.81 DHODH (0.42) LMNAALDH1A1POLBMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TSHR 2105/4885P2RX7 2406/4885TACR3 2928/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL TSHR 2105/4885P2RX7 2406/4885TACR3 2928/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TSHR 2105/4885P2RX7 2406/4885TACR3 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.